Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Medivation
>
Medivation Value
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 5660710"]Explanation of Medivation stock and Market cap value.</p><p><br /></p><p>Folks can conduct their own research to verify:</p><p><br /></p><p>Xtandi, Enzalutamide, is a great product which is offered to patients with Stage IV, Metastatic Castration Resistant Prostate Cancer, mCRPC.</p><p><br /></p><p>Medivation shares from sales of Xtandi is: 50% from US Market and around 30% from rest of the world. Rest goes to Astellas. They share the development cost in a more complex rates.</p><p><br /></p><p>In a similar setting there are few other therapies but the one in close competition is Abiraterone Acetate, marketed by J&J.</p><p><br /></p><p>Abiraterone Acetate has a bigger market share and in general is offered in a cheaper price. 2nd and most important of its patent, will be expiring on Dec 2016. This means, most likely, generic Abiraterone acetate will be available in USA by early 2017 and most likely in parity with Xtandi in CMS and all other insurance companies. Therefore allowing doctors to prescribe the much cheaper generic drug, Abiraterone, first and then upon disease progression allowing the use of Xtandi. This means duration of use for Xtandi will most likely be diminishing in USA and elsewhere.</p><p><br /></p><p>Xtandi patent loss of exclusivity in Europe is end of 2021.</p><p><br /></p><p>In reality, current trials of Xtandi in earlier Prostate Cancer are not going well and there are issues with patient enrollment and etc, and in general and in my professional opinion chance of trial success, is less than 15%. Also, the competitor of Xtandi in earlier Prostate Cancer is ARN 509 drug being under develop by J&J, which is a more potent version of Xtandi. They are by far ahead of Medivation and Astellas in their development efforts of Xtandi in earlier Prostate Cancer.</p><p>The Xtandi trial in Breast Cancer is just for a show and was not built based on solid data and has less then 10% Chance of success.</p><p><br /></p><p>Other two compounds owned and under development by Medivation are also nothing to write home about. Their so called Immunotherapy drug is not a true check point inhibitor and there is not much hope for this drug and even if they go full speed ahead with their development with this drug, by the time they come to the market, they will be far behind similar compounds already in the market by BMS, Merck and etc.</p><p><br /></p><p>Last compound owned by Medivation, is their last purchase from Biomarin Pharma. There was a reason, Biomarin sold this compound to Medivation. I would ask you to conduct your own search about the possibility of this drug having positive Phase III data in Breast Cancer.</p><p><br /></p><p>So, therefore one should prove why Medivation stock should be $56.00 and why Market cap should be worth nearly 9.3 Billion? In my opinion, this is a bubble produced by hedge funds and other entities. The Math does not makes sense and in my opinion, Medivation stock should not be and are not worth more than $20.00/share with market cap of near $6 billions at most.</p><p><br /></p><p>I don't hold any stocks in any company. I wish for good drugs to be accessible with a reasonable price to all patients. Also, for public to know and investors not to lose their money.</p><p><br /></p><p>Sincerely;</p><p>Concern Citizen[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 5660710"]Explanation of Medivation stock and Market cap value. Folks can conduct their own research to verify: Xtandi, Enzalutamide, is a great product which is offered to patients with Stage IV, Metastatic Castration Resistant Prostate Cancer, mCRPC. Medivation shares from sales of Xtandi is: 50% from US Market and around 30% from rest of the world. Rest goes to Astellas. They share the development cost in a more complex rates. In a similar setting there are few other therapies but the one in close competition is Abiraterone Acetate, marketed by J&J. Abiraterone Acetate has a bigger market share and in general is offered in a cheaper price. 2nd and most important of its patent, will be expiring on Dec 2016. This means, most likely, generic Abiraterone acetate will be available in USA by early 2017 and most likely in parity with Xtandi in CMS and all other insurance companies. Therefore allowing doctors to prescribe the much cheaper generic drug, Abiraterone, first and then upon disease progression allowing the use of Xtandi. This means duration of use for Xtandi will most likely be diminishing in USA and elsewhere. Xtandi patent loss of exclusivity in Europe is end of 2021. In reality, current trials of Xtandi in earlier Prostate Cancer are not going well and there are issues with patient enrollment and etc, and in general and in my professional opinion chance of trial success, is less than 15%. Also, the competitor of Xtandi in earlier Prostate Cancer is ARN 509 drug being under develop by J&J, which is a more potent version of Xtandi. They are by far ahead of Medivation and Astellas in their development efforts of Xtandi in earlier Prostate Cancer. The Xtandi trial in Breast Cancer is just for a show and was not built based on solid data and has less then 10% Chance of success. Other two compounds owned and under development by Medivation are also nothing to write home about. Their so called Immunotherapy drug is not a true check point inhibitor and there is not much hope for this drug and even if they go full speed ahead with their development with this drug, by the time they come to the market, they will be far behind similar compounds already in the market by BMS, Merck and etc. Last compound owned by Medivation, is their last purchase from Biomarin Pharma. There was a reason, Biomarin sold this compound to Medivation. I would ask you to conduct your own search about the possibility of this drug having positive Phase III data in Breast Cancer. So, therefore one should prove why Medivation stock should be $56.00 and why Market cap should be worth nearly 9.3 Billion? In my opinion, this is a bubble produced by hedge funds and other entities. The Math does not makes sense and in my opinion, Medivation stock should not be and are not worth more than $20.00/share with market cap of near $6 billions at most. I don't hold any stocks in any company. I wish for good drugs to be accessible with a reasonable price to all patients. Also, for public to know and investors not to lose their money. Sincerely; Concern Citizen[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Medivation
>
Medivation Value
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Medivation
>
Medivation Value
>